Table 3. Survival analysis by stratified groups adjusted for patient features and surgery (n=119 600).
| Years | Number of patients (n) | Proportions of patients (%) | HR (95% CI)a | Annual HR (95% CI)a | HR (95% CI)b | Annual HR (95% CI)b |
|---|---|---|---|---|---|---|
|
Whole cohort | ||||||
| 2004–2010 |
119 600 |
100 |
0.99 (0.98–0.99) |
|
0.99 (0.98–0.99) |
|
|
Group 1 = PS 0/1/2 and stage IA–IIB | ||||||
| 2004/2005 | 1098 | 7.2 | 1 | 1 | ||
| 2006 | 1206 | 7.8 | 0.98 (0.89–1.08) | 0.98 (0.89–1.09) | ||
| 2007 | 1567 | 8.7 | 0.90 (0.82–0.99) | 0.94 (0.85–1.03) | ||
| 2008 | 2038 | 9.4 | 0.85 (0.77–0.93) | 0.97 (0.95–0.99) | 0.91 (0.83–1.00) | 0.99 (0.97–1.00) |
| 2009 | 3166 | 12.7 | 0.75 (0.68–0.82) | 0.82 (0.75–0.90) | ||
| 2010 |
3545 |
14.4 |
0.74 (0.67–0.81) |
|
|
|
|
Group 2 = PS 0/1/2 and stage IIIA | ||||||
| 2004/2005 | 496 | 3.2 | 1 | 1 | ||
| 2006 | 609 | 3.9 | 1.00 (0.88–1.13) | 0.96 (0.85–1.09) | ||
| 2007 | 746 | 4.1 | 1.00 (0.89–1.13) | 0.97 (0.86–1.10) | ||
| 2008 | 926 | 4.2 | 1.06 (0.94–1.19) | 0.98 (0.96–0.99) | 1.07 (0.95–1.20) | 1.00 (0.97–1.02) |
| 2009 | 1387 | 5.6 | 0.95 (0.85–1.06) | 0.96 (0.85–1.07) | ||
| 2010 |
1957 |
7.9 |
0.91 (0.81–1.02) |
|
|
|
|
Group 3 = PS 0/1/2 and stage IIIB | ||||||
| 2004/2005 | 906 | 6 | 1 | 1 | ||
| 2006 | 1034 | 6.7 | 0.97 (0.89–1.06) | 0.96 (0.87–1.05) | ||
| 2007 | 1299 | 7.2 | 0.95 (0.87–1.04) | 0.97 (0.88–1.05) | ||
| 2008 | 1789 | 8.2 | 0.90 (0.83–0.98) | 0.99 (0.97–1.00) | 0.92 (0.84–1.00) | 1.00 (0.98–1.01) |
| 2009 | 2423 | 9.7 | 0.89 (0.82–0.97) | 0.91 (0.84–0.98) | ||
| 2010 |
1909 |
7.7 |
0.89 (0.82–0.98) |
|
|
|
|
Group 4 = PS 3/4 and stage IA–IIIA | ||||||
| 2004/2005 | 261 | 1.7 | 1 | |||
| 2006 | 211 | 1.3 | 1.16 (0.96–1.40) | |||
| 2007 | 338 | 1.8 | 1.19 (1.00–1.40) | |||
| 2008 | 481 | 2.2 | 1.10 (0.94–1.28) | 0.98 (0.95–1.01) | c | c |
| 2009 | 745 | 3 | 1.04 (0.89–1.21) | |||
| 2010 |
1077 |
4.3 |
1.17 (1.01–1.35) |
|
|
|
|
Group 5 = PS 0–4, stage IV and PS 3/4, stage IIIB | ||||||
| 2004/2005 | 2704 | 17.9 | 1 | |||
| 2006 | 2995 | 19.4 | 0.97 (0.92–1.03) | |||
| 2007 | 4054 | 22.5 | 0.97 (0.93–1.02) | |||
| 2008 | 6054 | 27.9 | 1.01 (0.97–1.06) | 1.01 (1.00–1.02) | c | c |
| 2009 | 8748 | 35.2 | 0.98 (0.94–1.02) | |||
| 2010 |
10 129 |
41.1 |
1.07 (1.02–1.11) |
|
|
|
|
Missing = either PS or stage missing | ||||||
| 2004/2005 | 9622 | 63.7 | 1 | |||
| 2006 | 9317 | 60.4 | 1.01 (0.98–1.04) | |||
| 2007 | 10 015 | 57.5 | 1.02 (0.99–1.06) | |||
| 2008 | 10 362 | 47.8 | 0.97 (0.94–1.00) | 0.99 (0.98–0.99) | c | c |
| 2009 | 8358 | 33.6 | 0.94 (0.91–0.97) | |||
| 2010 | 6028 | 24.4 | 0.96 (0.93–1.00) | |||
Abbreviations: CI=confidence interval; HR=hazard ratio; PS=performance status.
a
Hazard ratios adjusted for sex, age, ethnicity, co-morbidity and source of referral.
b
Hazard ratios adjusted for sex, age, ethnicity, co-morbidity, source of referral and surgery.
c
Hazard ratios not adjusted for surgery (surgery unlikely to be curative).